Eric Halioua steps down as chief executive of Promethera Biosciences

23 January 2015

Belgian pharma company Promethera Biosciences has announced the resignation of its chief executive Eric Halioua.

He has been chief executive of the company since its foundation in 2009, and is leaving in order to concentrate on other projects. Mr Halioua set up the staffing structure and took its lead candidate Hepastem into Phase I/II trials for orphan diseases such as Crigler-Najjar syndrome and urea cycle disorder.

While the search for a successor is underway, the chairman of the board of directors, John Tchelingerian, will assume the role of acting chief executive.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK